Dec 11, 2024, 14:33
Samer Al Hadidi: Oral Myeloma – Majestec-4/EMN30 presented at ASH24
Samer Al Hadidi, Assistant Professor at UAMS Myeloma Center, shared a post on X:
“ASH24 The American Society of Hematology (ASH)
Oral Myeloma: Majestec-4/EMN30
Schema:
Patients got 3-4 drugs with 1-2 transplants and needed to have at least partial response
Maintenance study:
Dosing intensity per 3 cohorts Tec can be stopped after 1 year if in CR and at 2 years regardless, details.”
More posts featuring Samer Al Hadidi.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 11, 2024, 14:53
Dec 11, 2024, 14:33
Dec 11, 2024, 14:33
Dec 11, 2024, 14:33
Dec 11, 2024, 14:33
Dec 11, 2024, 14:33
Dec 11, 2024, 14:33
Dec 11, 2024, 13:22